FMS acquires NXTM for $30/sh in cash—a 30% premium to Friday’s closing price: https://finance.yahoo.com/news/fresenius-medical-care-acquire-nxstage-054100095.html Consolidation in the dialysis business continues. The nominal deal value is $2.0B.